Focused studies of IGH rearrangements in myeloid neoplasms identified an IGH-CCNG1 breakpoint translocation at the cyclin G1 (CCNG1) promoter, which demonstrated overexpression of CCNG1 in the patient’s bone marrow (Xiao et al., 2020). Here, CCNG1 is linked to myeloid neoplasm.